Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: ixhl), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Incannex Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Incannex Healthcare's regulatory disclosures and financial reporting.
Incannex Healthcare (IXHL) reported an insider equity grant. The company’s CFO, Treasurer and Secretary received 869,565 shares of common stock at $0 on 11/14/2025, reported as an acquisition. Following the grant, beneficial ownership stands at 921,358 shares, held directly. The award is restricted stock under the 2023 Equity Incentive Plan, vesting in three equal tranches of 289,855 shares on 12/10/2025, 06/30/2026, and 06/30/2027.
Incannex Healthcare (IXHL) reported an insider equity grant on Form 4. CEO/President and Director Joel Latham acquired 22,608,692 shares of common stock on November 14, 2025 at a price of $0 (transaction code A). Following the grant, his beneficial ownership stands at 24,186,177 shares, held directly.
The filing states these are restricted shares granted under the company’s 2023 Equity Incentive Plan, with vesting in four equal tranches of 5,652,173 shares each: December 10, 2025, June 30, 2026 (two tranches), and June 30, 2027. This outlines the schedule by which the award becomes fully vested over time.
Incannex Healthcare (IXHL) director George Anastassov reported an acquisition of 1,686,956 shares of common stock on 11/14/2025, at a reported price of $0, reflecting a restricted stock grant under the 2023 Equity Incentive Plan. Following the transaction, he beneficially owns 2,456,677 shares, held directly.
The grant includes four equal tranches of 421,739 shares scheduled to vest on Dec 10, 2025, Jun 30, 2026 (two tranches), and Jun 30, 2027.
Incannex Healthcare Inc. (IXHL) filed a Form S-8 to register an additional 69,541,101 shares of common stock issuable under its 2023 Equity Incentive Plan, as amended on May 27, 2025, pursuant to the plan’s “evergreen” provision. The filing incorporates prior S-8 registrations for the same plan by reference under General Instruction E.
This expands the share pool available for employee and director equity awards and maintains continuity with the company’s existing plan framework.
Incannex Healthcare Inc. filed a current report to let investors know it has issued a new shareholder update. On October 30, 2025, the company provided an overview for shareholders that highlights its clinical progress, capital discipline, and end‑of‑year 2025 strategic focus.
The details of this update are contained in a press release attached as Exhibit 99.1 to the report, which is incorporated by reference into the filing. The company’s common stock continues to trade on the Nasdaq Stock Market under the symbol IXHL.
Incannex Healthcare Inc. will hold its 2025 annual meeting in a hybrid format at 10:00 a.m. Gulf Standard Time on December 18, 2025, with virtual access and an in‑person option in Dubai.
Stockholders are asked to elect two Class II directors—Dr. George Anastassov and Robert Clark—for three-year terms ending in 2028, and to ratify Grant Thornton Audit Pty Ltd as independent registered public accounting firm for the fiscal year ending June 30, 2026. The board recommends approval of both proposals.
Holders of common stock at the close of business on October 24, 2025 may vote. Shares outstanding were 347,705,507 as of that date. Director elections will be decided by a plurality of votes cast; auditor ratification requires a majority of voting power present and entitled to vote.
Incannex Healthcare (IXHL)
The company reported this under Item 8.01 on October 22, 2025. Further details are available in a press release furnished as Exhibit 99.1.
Incannex Healthcare (IXHL) reported a Nasdaq compliance update. The company received a second 180-day grace period, until April 20, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price rule. The extension follows IXHL’s July transfer from the Nasdaq Global Market to the Nasdaq Capital Market, where it meets all initial listing standards except the bid price requirement.
IXHL can regain compliance if its closing bid price is at least $1.00 for 10 consecutive business days, which Nasdaq may extend to 20 days at its discretion. The company stated it intends to cure the deficiency, including by effecting a reverse stock split if necessary. IXHL’s shares continue to trade on the Nasdaq Capital Market while it remains subject to the market’s other continued listing requirements.
Incannex Healthcare Inc. (IXHL) is an R&D-focused clinical-stage company developing three lead drug candidates: IHL-42X (for obstructive sleep apnea), PSX-001 (psilocybin-based therapy) and IHL-675A (inflammatory and autoimmune indications). Clinical data disclosed for IHL-42X show statistically significant reductions in AHI versus placebo (maximum reductions up to 83% high-dose, 79% low-dose) and clinically meaningful improvements in patient-reported outcomes including fatigue and sleep impairment. Financially the company reported continuing operating losses ($23.8M loss from operations) and net cash outflows from operations (~$12.5M for FY 2025). The company raised gross proceeds of ~$12.5M from an equity offering (9.687M shares at $1.08) and undertook financings, debenture repayments and warrant cancellations during the year. Material risks highlighted include dependence on R&D tax incentives, need for DEA scheduling and FDA/other regulatory approvals, potential listing risk on Nasdaq, and ongoing cash requirements to advance pivotal programs.
FAQ
What is the current stock price of Incannex Healthcare (ixhl)?
What is the market cap of Incannex Healthcare (ixhl)?
